Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Acrivon Therapeutics Q3 2026 Results: Net Loss of $17.9M, Loss Narrows

For the nine months ended September 30, 2026, Acrivon Therapeutics reported a net loss of $54.9 million, a slight improvement from the $58.9 million loss in the prior year period. The company's cash position decreased to $47.5 million from $41.5 million at year-end 2025, while short-term investments dropped significantly from $77.1 million to $30.2 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-17.9-18.2
EPS (diluted, $ a share)$-0.42$-0.47

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ACRV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Acrivon Therapeutics, Inc.: key numbers

Share price
$1.43Close, Nov 17
Market cap
$61.4M
Shares outstanding
42.91MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Acrivon Therapeutics, Inc.

All →
4:09 PM ET 8-K
Financial Results

Acrivon Therapeutics Financial Results

Acrivon Therapeutics reported Q3 2026 financial results, ending the period with $77.8 million in cash and marketable securities, which is expected to fund operations into Q4 2027. The company highlighted its strategic expansion into immunology and inflammation (I&I) with the acquisition of ACR-525 and provided updates on its clinical pipeline, including upcoming Phase 2b interim data for ACR-368.

Term
Q3 2026

“We have had transformative progress this year, including the strategic expansion into immunology and inflammation and the positive clinical results in tumor types predicted sensitive by AP3 to our internally developed, first-in-class WEE1/PKMYT1 inhibitor ACR-2316, laying the foundation for multiple upcoming value-inflection milestones.”

Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon
4:56 PM ET 8-K
Investor Presentation

Acrivon Therapeutics Investor Presentation

Acrivon Therapeutics hosted a corporate R&D event and webcast featuring Key Opinion Leaders to introduce its new immunology and inflammation (I&I) programs, ACR-525 and a PKCθ inhibitor. The company filed a formal investor presentation deck detailing the preclinical programs and development plans for Eosinophilic esophagitis (EoE) identified via its AP3 platform.

8:00 AM ET 8-K
M&A Deal

Acrivon Therapeutics M&A Deal with Aqilion AB

Acrivon Therapeutics has acquired a portfolio of immunology and inflammation (I&I) assets from Swedish biotech Aqilion AB, including the Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKCθ inhibitor program. The deal establishes I&I as a new strategic pillar for Acrivon, which plans to apply its AP3 precision medicine platform to these assets for indications such as Eosinophilic esophagitis (EoE).

Counterparty
Aqilion AB

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.